News & Events
Lonza and Celladon Corporation Establish a Strategic Commercial Manufacturing Collaboration
05 / 11 / 2014
Celladon Corporation Announces Publication of Data
27 / 10 / 2014
New Gene Therapy Approach Shown To Reverse Heart Damage and Improve Long Term Cardiac Function Following Myocardial Infarction in Animal Models.
Ivantis Announces HYDRUS II Glaucoma Study Met Primary Endpoint In a Randomized Controlled Trial
24 / 10 / 2014
Results from Landmark International Study Show Hydrus™ Microstent Significantly Reduced Intraocular Pressure and Medication Use in Patients with Glaucoma Undergoing Cataract Surgery
Updated Clinical Data from Numerous Studies of AirXpanders' AeroForm
14 / 10 / 2014
Clinical data consistently show that patients undergoing breast reconstruction after a mastectomy can complete expansion significantly faster with AeroForm™ expanders than traditional saline expanders Separate analyses show that it is safe to fly with AeroForm implanted and patients can undergo radiation therapy for residual breast cancer while completing the expansion process
Neurovance Appoints Brigitte Robertson, MD, Vice President, Clinical Development
05 / 08 / 2014
Dr. Robertson Brings ADHD Expertise to Advance Neurovance’s Centanafadine SR Program Neurovance’s Lead Product EB-1020 SR Granted Non-Proprietary Name; Now Called Centanafadine SR
Celladon Corporation Secures $25 Million Credit Facility from Hercules Growth Capital
01 / 08 / 2014
Celladon Corporation Announces In-License of Stem Cell Factor Development Program
21 / 07 / 2014
License Brings Novel Gene Therapy Approach for in situ Targeting of Multi-Potent Stem Cells for the Heart